Rezai, 609 patient ivermectin late treatment RCT: 31% lower mortality [p=0.36], 50% lower ventilation [p=0.07], 16% lower ICU admission [p=0.47], and 11% longer hospitalization [p=0.009] https://c19p.org/rezai2
copied to clipboard
Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials
et al., Frontiers in Medicine, doi:10.3389/fmed.2022.919708
RCT 609 inpatients in Iran. Reported outcomes are very different from the pre-specified outcomes [irct.ir]. The outpatient trial is listed separately. From the pre-specified outcomes, all are either positive or not reported. Pre-specified outcomes:- Reduction in persistent cough - RR 0.36 p = 0.06
- Negative RT-PCR - not reported
- Main complaints recovery time - not reported
- Mortality - RR 0.69 p = 0.36
- Side effects - reported as none (anomalous)
- Reduction in tachypnea - RR 0.24 p = 0.38
- Oxygen saturation >94% - not reportedAll negative outcomes are protocol violations and are not listed in the protocol, including the novel ""relative recovery" outcome.Authors include a researcher caught on video admitting that conclusions on ivermectin research were influenced by a funder [c19ivermectin.com].Severe cases were more frequent in the ivermectin group, 49% vs. 43%.Dose was limited at a maximum of 30mg for 75+kg, resulting in underdosing for patients at higher risk.Almost all patients received remdesivir, most patients received famotidine and vitamin C, and many patients received vitamin D, metformin, and zinc, limiting room for improvement.32% of patients were lost to followup.Authors indicate bottles were identical, but tablets were only similar.Ivermectin was obtained from Alborz Daru Co.
- Negative RT-PCR - not reported
- Main complaints recovery time - not reported
- Mortality - RR 0.69 p = 0.36
- Side effects - reported as none (anomalous)
- Reduction in tachypnea - RR 0.24 p = 0.38
- Oxygen saturation >94% - not reportedAll negative outcomes are protocol violations and are not listed in the protocol, including the novel ""relative recovery" outcome.Authors include a researcher caught on video admitting that conclusions on ivermectin research were influenced by a funder [c19ivermectin.com].Severe cases were more frequent in the ivermectin group, 49% vs. 43%.Dose was limited at a maximum of 30mg for 75+kg, resulting in underdosing for patients at higher risk.Almost all patients received remdesivir, most patients received famotidine and vitamin C, and many patients received vitamin D, metformin, and zinc, limiting room for improvement.32% of patients were lost to followup.Authors indicate bottles were identical, but tablets were only similar.Ivermectin was obtained from Alborz Daru Co.
|
risk of death, 30.8% lower, RR 0.69, p = 0.36, treatment 13 of 311 (4.2%), control 18 of 298 (6.0%), NNT 54.
|
|
risk of mechanical ventilation, 50.0% lower, RR 0.50, p = 0.07, treatment 311, control 298.
|
|
risk of ICU admission, 16.0% lower, RR 0.84, p = 0.47, treatment 311, control 298.
|
|
hospitalization time, 11.5% higher, relative time 1.11, p = 0.009, treatment mean 7.98 (±4.4) n=311, control mean 7.16 (±3.2) n=298.
|
|
deterioration, 12.7% higher, RR 1.13, p = 0.74, treatment 20 of 311 (6.4%), control 17 of 298 (5.7%).
|
|
risk of no recovery, 24.2% lower, RR 0.76, p = 0.02, treatment 311, control 298, post-hoc primary outcome.
|
|
risk of no recovery, 64.0% lower, RR 0.36, p = 0.06, treatment 5 of 145 (3.4%), control 10 of 105 (9.5%), NNT 16, day 7, cough.
|
|
risk of no recovery, 76.0% lower, RR 0.24, p = 0.38, day 7, tachypnea.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
multiple critical issues, see study page.
Rezai et al., 6/16/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, Middle East, peer-reviewed, mean age 53.8, 29 authors, study period 19 February, 2021 - 14 August, 2021, average treatment delay 7.18 days, dosage 400μg/kg days 1-3, trial IRCT20111224008507N5.
Contact:
drmsrezaii@yahoo.com.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.